Osteoblastic Progression during EGFR Tyrosine Kinase Inhibitor Therapy in Mutated Non-small Cell Lung Cancer: A Potential Blunder. Issue 1 (January 2017)

• Record Type: Journal Article
• Authors: Bersanelli, Melissa; Bini, Paola; Rabaiotti, Enrico; Facchinetti, Francesco; De Filippo, Massimo; Bortesi, Beatrice; Buti, Sebastiano; Tiseo, Marcello
• Is Part Of: Tumori. Volume 103:Issue 1(2017)
• Page Start: 66
• Page End: 71
• Publication Date: 2017-01
• Subjects: Bone metastasis -- Computed tomography scan -- Epidermal growth factor receptor mutations -- Non-small cell lung cancer -- Osteoblastic reaction -- Tyrosine kinase inhibitor; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000423
• Languages: English
• ISSNs: 0300-8916

Abstract

Aims and background: Bone flare reaction as a sign of response to antineoplastic treatment has been redefined, including the onset of new osteoblastic lesions. If misunderstood as skeletal progression, this finding could lead to erroneous therapy discontinuation, changing the disease clinical course. We aim to describe this clinical phenomenon in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) gene-activating mutations treated with tyrosine kinase inhibitor (TKI). Methods: We retrospectively reviewed the computed tomography scans of 43 EGFR -mutated patients with NSCLC treated with EGFR-TKI, analyzing the bone response in terms of increase in the quantity and/or density of lesions, and assessing objective tumor response to treatment. Results: Osteoblastic reaction was detected in 10 cases (23%), showing different patterns: dimensional or density increase of known osteosclerotic metastases (pattern A, n = 4); response of previously lytic lesions (pattern B, n = 2); onset of new osteosclerotic lesions (pattern C, n = 4). Seven patients had partial response to TKI treatment, with response rate of 70%, vs 50% of patients with bone metastases without this reaction. No difference in terms of median overall survival or progression-free survival emerged between patients with or without osteoblastic reaction. Conclusions: The correct clinico-radiologic interpretation of osteoblastic reaction is crucial to avoid waste of therapeutic lines when TKI treatment has not yet exhausted its potential effectiveness. Clinical implications of ambiguous radiologic findings as described in this study deserve further discussion.